The UK and US have secured a significant commercial pact that will keep zero duties on UK pharmaceutical products being sold in the US market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has agreed to increase spending on pharmaceuticals through the NHS. This commitment guarantees that duties on these crucial products will stay at nothing for a timeframe of three years.
This deal follows earlier statements to significantly raise duties on branded drug products, with increases mentioned up to one hundred percent.
"This agreement with the United Kingdom strengthens the global environment for new treatments and brings much-needed fairness to American-British drug exports," a statement noted.
Trade Significance
Pharmaceuticals are one of the the United Kingdom's biggest exports to the US, which is easily the largest destination for leading UK drugmakers.
Statistics reveal that in the 12 months to the end of last September, the UK sold medicines valued at £11.1bn to the US. This value represented 17.4% of all goods exports in that timeframe.
"This agreement secures work, stimulates funding and paves the way for the UK to become a worldwide center for life sciences," a minister remarked.
Specific British Pledges
The deal includes several specific commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the price threshold at which it deems new therapies to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a goal to raise overall public funding on drugs from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Refund Ceiling: The amount manufacturers must return to the NHS to prevent overspending will be limited at 15%. Previously, refunds were more than twenty percent.
Industry Background
This agreement takes place against a protracted tension between the pharmaceutical industry and the UK government over drug pricing and approval rates.
This friction were intensified by claims that US consumers were charged significantly more for the same drugs than patients in the other developed nations.
Over the last 18 months, several large manufacturing plans in the UK have been delayed or scrapped, while substantial expansions have been pledged toward projects in the United States.
The Science Minister stated that the NHS had to invest a greater share on treatments, noting that its spending on drugs had declined as a proportion of its total funding over the previous ten-year period.
